Lupus Nephritis Market Report 2026

The lupus nephritis market size has grown strongly in recent years. It will grow from $2.08 billion in 2025 to $2.24 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing prevalence of systemic lupus erythematosus, improved kidney biopsy and diagnostic practices, widespread use of corticosteroids in treatment, growing hospital-based nephrology care, increased awareness of autoimmune kidney diseases.

The lupus nephritis market size is expected to see strong growth in the next few years. It will grow to $2.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising investment in biologic drug development, increasing focus on early intervention to prevent kidney failure, growing adoption of combination therapy regimens, expansion of specialty nephrology clinics, increasing healthcare spending on autoimmune disease management. Major trends in the forecast period include rising focus on early diagnosis and disease monitoring, growing adoption of immunosuppressive and biologic therapies, increasing emphasis on personalized treatment approaches, expansion of long-term disease management strategies, rising awareness of autoimmune kidney complications.

The rising prevalence of genetic predisposition is anticipated to drive the growth of the lupus nephritis market in the coming years. Genetic predisposition refers to inherited genetic characteristics that increase an individual’s risk of developing certain diseases or conditions. The growing prevalence of genetic predisposition is attributed to factors such as heredity, environmental exposure, and mutations in specific genes. The increasing prevalence of genetic predisposition plays a crucial role in the onset of lupus nephritis, highlighting the influence of inherited genetic factors in autoimmune disorders, particularly those that affect kidney function. For example, in October 2024, according to the Cystic Fibrosis Trust, a UK-based national charity, the UK CF Registry reported 11,148 registered patients in 2022, which rose to 11,318 in 2024, representing a 1.52% increase in individuals living with cystic fibrosis (CF). Hence, the growing prevalence of genetic predisposition is contributing to the expansion of the lupus nephritis market.

Major players in the lupus nephritis market are concentrating on the development of advanced second-generation calcineurin inhibitors to improve therapeutic effectiveness and support better long-term kidney outcomes. Second-generation calcineurin inhibitors help manage lupus nephritis by suppressing immune activity, thereby reducing inflammation and limiting kidney damage. For example, in September 2024, Aurinia Pharmaceuticals Inc., a Canada-based commercial-stage biopharmaceutical company, announced that Japan’s Ministry of Health, Labour, and Welfare approved LUPKYNIS (voclosporin) for the treatment of lupus nephritis. This approval permits the use of voclosporin in combination with mycophenolate mofetil (MMF), supported by results from the AURORA Clinical Program that demonstrated both its safety and efficacy. This decision represents an important step in broadening available treatment options for lupus nephritis patients in Japan and enhancing overall disease management and outcomes.

In March 2024, Lupus Therapeutics, a U.S.-based clinical research partner affiliated with the Lupus Research Alliance, entered into a partnership with Artiva Biotherapeutics Inc. to advance a clinical trial for lupus nephritis. Through this collaboration, Lupus Therapeutics plans to initiate a Phase 1 study to assess Artiva’s AlloNK therapy in combination with anti-CD20 antibodies for patients with active lupus nephritis, focusing on evaluating its safety and therapeutic potential in treating this severe renal complication. Artiva Biotherapeutics is a U.S.-based biotechnology company engaged in developing treatments for lupus nephritis.

Major companies operating in the lupus nephritis market are F Hoffmann La Roche Ltd, Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca PLC, Pfizer Inc, Johnson and Johnson, Merck and Co Inc, Sanofi, AbbVie Inc, Bayer AG, Amgen Inc, UCB SA, Otsuka Pharmaceutical Co Ltd, Aurinia Pharmaceuticals Inc, RemeGen Co Ltd, Kezar Life Sciences, Equillium Inc, Kyverna Therapeutics Inc, Biogen Inc.

Asia-Pacific was the largest region in the lupus nephritis market in 2025. The regions covered in the lupus nephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lupus nephritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the lupus nephritis market by increasing the cost of imported biologic agents, immunosuppressive drugs, and specialty pharmaceutical ingredients. These impacts are more pronounced in advanced therapy segments, particularly in asia-pacific and europe where treatment supply chains are globally integrated. Hospitals and specialty clinics face higher procurement costs and pricing pressures. However, tariffs have encouraged domestic manufacturing of immunosuppressive drugs, regional sourcing, and local clinical research investments, supporting long-term market resilience.

The lupus nephritis market research report is one of a series of new reports that provides lupus nephritis market statistics, including lupus nephritis industry global market size, regional shares, competitors with a lupus nephritis market share, detailed lupus nephritis market segments, market trends and opportunities, and any further data you may need to thrive in the lupus nephritis industry. This lupus nephritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lupus nephritis is a severe kidney disorder that develops as a complication of systemic lupus erythematosus (SLE), an autoimmune condition in which the immune system mistakenly targets healthy tissues, including the kidneys. The resulting inflammation can cause kidney injury and reduced kidney function, and if not treated in a timely manner, may progress to kidney failure, highlighting the importance of early detection and appropriate management.

The primary stages of lupus nephritis include class 1, class 2, class 3, and additional advanced classes. Class 1 represents an early stage characterized by minimal kidney involvement, where renal function remains largely unaffected and symptoms are usually absent. Management at this stage is aimed at preventing disease progression. Treatment options consist of immunosuppressive agents, corticosteroids, biologic therapies, and antimalarial medications, delivered via oral, parenteral, and other administration routes. These therapies are supplied through hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by end users such as hospitals, specialty clinics, and other healthcare settings.

The lupus nephritis market consists of revenues earned by entities by providing services such as dialysis services, diagnostic testing, renal care services, and home healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The lupus nephritis market also consists of sales of medical devices, diagnostic products, and renal replacement products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.